[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

No Subject


Keryx to Start Late-Stage Trials on Kidney Drug for Diabetics
Bloomberg News
Sep 27 2000 10:12AM

Jerusalem, Sept. 27 (Bloomberg) -- Keryx Biopharmaceuticals Inc., an Israeli 
drugmaker that went public in July, said it will start late-stage clinical 
trials for a drug to treat kidney damage in diabetics.

Keryx will work with the U.S. Food and Drug Administration to develop a trial 
protocol for KRX-101, it said in a statement released on the PRNewswire in the 

The company's shares have risen 30 percent since it first went public on July 
27. It has another drug, KRX 123, for the treatment of prostate cancer, about 
to enter clinical trials.

``Diabetic nephropathy is a tragic condition for millions of people,'' said 
Morris Laster, chairman and chief executive of Keryx, in a statement. 
``Eventually, we hope to be able to mitigate this life-threatening medical 
condition that afflicts such a substantial percentage of diabetic patients 

Keryx shares rose 80 pence, or 10 percent, to 865p in late afternoon trading 
in London.

for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml